Our research and development projects are co-financed by the European Union.
Biotts S.A. is implementing a project co-financed by the European Funds:
“Development of an externally administered product containing an innovative carrier allowing percutaneous transmission of antidiabetic substances and the pharmaceutical composition containing them”, under the Intelligent Development Operational Programme 2014-2020, Priority I “Support for conducting R&D works by enterprises”, Sub-measure 1.1.1. project number: POIR.01.01.01-00-0629/19.
The aim of the project is to develop a new form of antidiabetic drug (with selected API) with an increased release profile and a safer application for patients with type 2 diabetes mellitus through the use of the innovative BIOTTS carrier.
EU funding of the project: 11 200 598.88 PLN
Project value: PLN 14 677 245.75
BIOTTS S.A. implements a project co-financed by European Funds
“Obtaining international patent protection for an invention concerning a pharmaceutical carrier for active substances and a pharmaceutical composition containing it”, within the framework of the Operational Programme Intelligent Development 2014-2020, Priority Axis II: Support for the environment and the potential of enterprises to conduct R&D&I activities, Measure 2.3 Pro-innovative services for enterprises, Sub-measure 2.3.4 Protection of industrial property.
Project number POIR.02.03.03.04-02-0002-0002/19
Co-financing of the project from the EU: 363 745.00 PLN
Smart Growth Operational Programme 2014-2020
Measure 1.3, Sub-measure 1.3.1
Project title
BIOTTS, development of transdermal preparations used in the treatment of difficult-to-heal wounds and local anaesthetics.
Title of the programme
Smart Growth Operational Programme 2014-2020
Measure 1.3: R&D activity financed with capital funds
participation
Sub-measure 1.3.1: Support for R&D projects at the ‘pre-seed’ stage by
proof of concept funds – Bridge Alfa
Project value: 2 800 000.00 PLN
Contribution from European Funds: 2 240 000.00 PLN
Objective of the project
As part of the Bridge Alfa programme, Biotts implements a research and development project aimed at developing the Company, examining the formulas and introducing two candidates for drugs to the pre-clinical research phase.
Project duration: 01.08.2018 – 30.07.2020
Lower Silesian Innovation Voucher
Objective of the project
We will use the funds for the project that is to demonstrate the process of penetration of active substances attached to the universal carrier: MTC-Y through the skin and tissue layers based on the reference substance from the fluorochrome group. If a photoactive substance is introduced into a carrier, it will be possible to image and document the mechanism of active substances’ penetration through subsequent barriers.
Project number: RPDS.01.02.01-02-0002/17
Project value: 100 799,73 PLN
Public aid:
European Regional Development Fund: 62 692,60 PLN
Budget of the Lower Silesian Voivodeship: 11 063,40 PLN
The “Lower Silesian Innovation Voucher” project is co-financed by the European Union from the ERDF under Measure 1.2C of the Regional Operational Programme of the Lower Silesian Voivodeship 2014-2020, implemented by the Office of the Marshal of the Lower Silesian Voivodeship (UMWD) and the Lower Silesian Regional Development Agency (DARR S.A.)
